Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket tria... von Bardia, A., Messersmith, W.A., Kio, E.A., Berlin, J.D., Vahdat, L., Masters, G.A., Moroose, R., Santin, A.D., Kalinsky, K., Picozzi, V., O'Shaughnessy, J., Gray, J.E., Komiya, T., Lang, J.M., Chang, J.C., Starodub, A., Goldenberg, D.M., Sharkey, R.M., Maliakal, P., Hong, Q., Wegener, W.A., Goswami, T., Ocean, A.J.

Volltext

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach von Lassen, U N, Albert, C M, Kummar, S, van Tilburg, C M, Dubois, S G, Geoerger, B, Mascarenhas, L, Federman, N, Schilder, R J, Doz, F, Berlin, J D, Oh, D-Y, Bielack, S S, McDermott, R, Tan, D S, Cruickshank, S, Ku, N C, Cox, M C, Drilon, A, Hong, D S

Volltext

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 von Verslype, C., Van Cutsem, E., Dicato, M., Arber, N., Berlin, J. D., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Gruenberger, T., Haller, D., Haustermans, K., Hoff, P., Kerr, D., Labianca, R., Moore, M., Nordlinger, B., Ohtsu, A., Rougier, P., Scheithauer, W., Schmoll, H.-J., Sobrero, A., Tabernero, J., van de Velde, C.

Volltext

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high in... von Rodon, J., Rodriguez, E., Maitland, M.L., Tsai, F.Y.-C., Socinski, M.A., Berlin, J.D., Thomas, J.S., Al Baghdadi, T., Wang, I.-M., Guo, C., Golmakani, M., Clark, L.N., Gazdoiu, M., Li, M., Tolcher, A.W.

Volltext

Pancreas cancer on the rise: are we up to the challenge? von Cardin, Dana B, Berlin, Jordan D

Volltext

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer von Lenz, H.-J., Park, H., Shah, M.A., Berlin, J.D., Bruetman, D., Chaves, J., Gordon, M., Patel, R., Starodub, A., Liu, J., Baker Brachmann, C., Bhargava, P., Wainberg, Z.A., Bendell, J.

Volltext

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC) von Hays, J., Zhang, J., Berlin, J.D., O'Hara, M., Shah, M.A., Reichmann, W., Senapedis, W., Achour, H., Baloglu, E., Shacham, S., Kauffman, M.

Volltext

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach von Tan, D.S.W., Lassen, U.N., Albert, C.M., Kummar, S., van Tilburg, C., Dubois, S.G., Geoerger, B., Mascarenhas, L., Federman, N., Basu-Mallick, A., Doz, F., Berlin, J.D., Oh, D.-Y., Bielack, S., McDermott, R., Cruickshank, S., Ku, N.C., Cox, M.C., Drilon, A., Hong, D.S.

Volltext

The epidermal growth factor receptor as a target for colorectal cancer therapy von Lockhart, Craig, Berlin, Jordan D.

Volltext

A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296) von Berlin, Jordan D., Adak, Sudeshna, Vaughn, David J., Flinker, David, Blaszkowsky, Lawrence, Harris, Jules E., Al Bowen Benson III, A.B.

Volltext

Warfarin—5‐FU Interaction — A Consecutive Case Series von Kolesar, Jill M., Johnson, Carrie L., Freeberg, Betty L., Berlin, Jordan D., Schiller, Joan H.

Volltext

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors von BERLIN, J. D, ALBERTI, D. B, ARZOOMANIAN, R. Z, FEIERABEND, C. A, SIMON, K. J, BINGER, K. A, MARNOCHA, R. M, WILDING, G

Volltext

5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: An eastern cooperative oncology group phase II study (E1889) von BERLIN, J. D, PROPERT, K. J, TRUMP, D, WILDING, G, HUDES, G, GLICK, J, BURCH, P, KELLER, A, LOEHRER, P

Volltext

612PSPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escala... von Fakih, M G, Wang, D, Harb, W, Rosen, L, Mahadevan, D, Berlin, J D, Basciano, P, Brown, R, Arogundade, O, Cox, C, Genova, G Di, Krige, D, McElwaine-Johnn, H

Volltext

LBA23Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC) von Hays, J, Zhang, J, Berlin, J D, O'Hara, M, Shah, M A, Reichmann, W, Senapedis, W, Achour, H, Baloglu, E, Shacham, S, Kauffman, M

Volltext

567PResults of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer von Lenz, H-J, Park, H, Shah, M A, Berlin, J D, Bruetman, D, Chaves, J, Gordon, M, Patel, R, Starodub, A, Liu, J, Baker Brachmann, C, Bhargava, P, Wainberg, Z A, Bendell, J

Volltext

682PPhase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancr... von Tempero, M A, Reni, M, Riess, H, O’Reilly, E M, Krishnamurthi, S, Österlund, P, Ales-Diaz, I C, Milella, M, Siena, S, Tabernero, J, Van Cutsem, E, Philip, P A, Goldstein, D, Berlin, J D, Li, M, Ferrara, S, Bruchec, Y Le, McGovern, D, Biankin, A

Volltext

445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer von Hyman, D M, van Tilburg, C M, Albert, C M, Tan, D S W, Geoerger, B, Farago, A F, Laetsch, T W, Kummar, S, Doz, F, Lassen, U N, DuBois, S G, McDermott, R, Mascarenhas, L, Berlin, J D, Rudzinski, E R, Cox, M C, Nanda, S, Childs, B H, Drilon, A, Hong, D S

Volltext

409OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach von Lassen, U N, Albert, C M, Kummar, S, van Tilburg, C M, Dubois, S G, Geoerger, B, Mascarenhas, L, Federman, N, Schilder, R J, Doz, F, Berlin, J D, Oh, D-Y, Bielack, S S, McDermott, R, Tan, D S, Cruickshank, S, Ku, N C, Cox, M C, Drilon, A, Hong, D S

Volltext

69OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach von Tan, D S W, Lassen, U N, Albert, C M, Kummar, S, van Tilburg, C, Dubois, S G, Geoerger, B, Mascarenhas, L, Federman, N, Basu-Mallick, A, Doz, F, Berlin, J D, Oh, D-Y, Bielack, S, McDermott, R, Cruickshank, S, Ku, N C, Cox, M C, Drilon, A, Hong, D S

Volltext